- The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of HIV-specific protease inhibitors (PIs).
The 4 PIs available are saquinavir mesylate, ritonavir, indinavir sulfate, and nelfinavir mesylate.
Comparison studies have not been reported ; therefore, an assessment of the available data to aid clinicians and patients in choosing appropriate treatment will be presented.
- A systematic review of peer-reviewed publications, abstracts from national and intemational conferences, and product registration information through September 1996.
- Criteria used to select studies include their relevance to Pls, having been published in the English language, and pertinence for clinicians.
Data quality and validity included the venue of the publication and relevance to clinical care.
- Oral adminstration of ritonavir, indinavir, or nelfinavir generates sustainable drug serum levels to effectively inhibit the protease enzyme ; however, saquinavir may not generate sustained levels necessary to inhibit the protease enzyme, Patients treated with ritonavir, indinavir, or nelfinavir experience similar reductions in viral load and increases in CD4+lymphocytes ; smaller effects occur among those treated with saquinavir. (...)
Mots-clés Pascal : Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Inhibiteur protéique, Chimiothérapie, Modalité traitement, Critère sélection, Relation médecin malade, Pharmacocinétique, Interaction médicamenteuse, Aspect économique, Recommandation, Centre santé, Homme, Article synthèse, Saquinavir, Résistance, SIDA, Virose, Infection, Immunopathologie
Mots-clés Pascal anglais : HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Protein inhibitor, Chemotherapy, Application method, Selection criterion, Physician patient relation, Pharmacokinetics, Drug interaction, Economic aspect, Recommendation, Health center, Human, Review, Saquinavir, Resistance, AIDS, Viral disease, Infection, Immunopathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0127071
Code Inist : 002B06D01. Création : 21/05/1997.